FLOW

The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.

Definition

Semaglutide 1 mg weekly in chronic kidney disease with type 2 diabetes (NEJM 2024). The composite kidney outcome — eGFR decline, kidney failure, renal or CV death — fell 24%, HR 0.76.

FLOW trial: semaglutide in kidney disease →

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.

Other terms under Major trials

STEP-1
SURMOUNT-1
SELECT
SURMOUNT-OSA
STEP-TEENS
MACE (Major Adverse Cardiovascular Events)
KCCQ-CSS (Kansas City Cardiomyopathy Questionnaire — Clinical Summary Score)
ATTAIN-1
IWQOL-Lite-CT
STEP-4 (withdrawal trial)
SYNERGY-NASH
LEADER (trial)
FLOW (trial)

Where the evidence lives

FLOW trial: semaglutide in kidney disease
The full GLP-1 glossary (149 terms, 8 categories)
Research articles — written from primary sources
Tools and calculators
Compare GLP-1 telehealth providers